Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
19.65
USD
|
+3.42%
|
|
+12.09%
|
+36.65%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
623.1
|
2,157
|
931.8
|
847.2
|
1,068
|
1,497
|
-
|
-
|
Enterprise Value (EV)
1 |
393.7
|
1,838
|
841.1
|
804.5
|
1,068
|
1,497
|
1,497
|
1,497
|
P/E ratio
|
-9.11
x
|
-19.3
x
|
-7.11
x
|
-6.11
x
|
-6.91
x
|
-8.47
x
|
-8.15
x
|
-9.44
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
113
x
|
14.1
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
113
x
|
14.1
x
|
EV / EBITDA
|
-9.23
x
|
-23.5
x
|
-7.13
x
|
-6.09
x
|
-6.47
x
|
-7.63
x
|
-7.17
x
|
-5.06
x
|
EV / FCF
|
-11.4
x
|
-30
x
|
-8.82
x
|
-7.65
x
|
-8.54
x
|
-7.64
x
|
-7.64
x
|
-7.16
x
|
FCF Yield
|
-8.79%
|
-3.34%
|
-11.3%
|
-13.1%
|
-11.7%
|
-13.1%
|
-13.1%
|
-14%
|
Price to Book
|
2.64
x
|
2.84
x
|
1.83
x
|
1.98
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,315
|
66,035
|
66,556
|
68,264
|
74,272
|
76,181
|
-
|
-
|
Reference price
2 |
13.75
|
32.66
|
14.00
|
12.41
|
14.38
|
19.65
|
19.65
|
19.65
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
13.19
|
106.5
|
EBITDA
1 |
-67.48
|
-91.9
|
-130.7
|
-139.1
|
-165
|
-196.3
|
-208.7
|
-296
|
EBIT
1 |
-67.48
|
-91.9
|
-131.3
|
-139.9
|
-165.8
|
-205.1
|
-232.5
|
-187.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,762.18%
|
-175.73%
|
Earnings before Tax (EBT)
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-196.8
|
-225.8
|
-172.8
|
Net income
1 |
-63.14
|
-89.62
|
-130.5
|
-135.8
|
-152.6
|
-194
|
-216.1
|
-192.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,638.4%
|
-180.54%
|
EPS
2 |
-1.510
|
-1.690
|
-1.970
|
-2.030
|
-2.080
|
-2.321
|
-2.410
|
-2.081
|
Free Cash Flow
1 |
-54.76
|
-72
|
-105.7
|
-110.7
|
-125
|
-196
|
-196
|
-209
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,485.77%
|
-196.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-41.37
|
-33.68
|
-32.87
|
-32.6
|
-35.15
|
-36.4
|
-34.95
|
-36.36
|
-39.79
|
-42.26
|
-46.55
|
-47
|
-50.5
|
-51.3
|
-53.4
|
-
|
EBIT
1 |
-
|
-33.68
|
-33.04
|
-32.78
|
-35.33
|
-36.59
|
-35.16
|
-36.57
|
-40
|
-42.47
|
-46.76
|
-47.8
|
-50.17
|
-52.26
|
-54.88
|
-48.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-33.37
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-46.08
|
-47.97
|
-49.9
|
-52.86
|
-48
|
Net income
1 |
-
|
-33.37
|
-32.74
|
-32.45
|
-34.77
|
-35.5
|
-33.11
|
-34.07
|
-37.17
|
-38.6
|
-42.79
|
-45.25
|
-47.33
|
-49.28
|
-52.29
|
-48
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.5000
|
-0.4900
|
-0.4900
|
-0.5200
|
-0.5300
|
-0.4900
|
-0.5000
|
-0.5300
|
-0.5000
|
-0.5500
|
-0.5646
|
-0.5718
|
-0.5918
|
-0.6154
|
-0.5900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
11/4/21
|
2/24/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/23/23
|
5/10/23
|
8/3/23
|
11/2/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
229
|
318
|
90.7
|
42.6
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-54.8
|
-72
|
-106
|
-111
|
-125
|
-196
|
-196
|
-209
|
ROE (net income / shareholders' equity)
|
-33.3%
|
-21.6%
|
-23.3%
|
-29.3%
|
-37.3%
|
-43.5%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
212.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.220
|
11.50
|
7.640
|
6.270
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-1.310
|
-1.320
|
-1.580
|
-1.640
|
-1.610
|
-2.260
|
-1.780
|
1.520
|
Capex
1 |
-
|
2.17
|
1.15
|
0.63
|
0.17
|
1.46
|
1.6
|
1.77
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
12.13%
|
1.66%
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
19.65
USD Average target price
30.25
USD Spread / Average Target +53.94% Consensus |
1st Jan change
|
Capi.
|
---|
| +36.65% | 1.5B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|